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BACKGROUND
Patients with acute medical illnesses are at prolonged risk for venous thrombosis. 
However, the appropriate duration of thromboprophylaxis remains unknown.
METHODS
Patients who were hospitalized for acute medical illnesses were randomly assigned 
to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days 
plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin pla-
cebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 
42 days. We performed sequential analyses in three prespecified, progressively 
inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with 
an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the en-
rolled patients (overall population cohort). The statistical analysis plan specified 
that if the between-group difference in any analysis in this sequence was not 
significant, the other analyses would be considered exploratory. The primary ef-
ficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis 
and symptomatic venous thromboembolism. The principal safety outcome was 
major bleeding.
RESULTS
A total of 7513 patients underwent randomization. In cohort 1, the primary effi-
cacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving 
enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 
0.65 to 1.00; P = 0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 
0.80; 95% CI, 0.66 to 0.98; P = 0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 
95% CI, 0.63 to 0.92; P = 0.006) in the overall population. (The last two analyses 
were considered to be exploratory owing to the result in cohort 1.) In the overall 
population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of 
the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P = 0.55).
CONCLUSIONS
Among acutely ill medical patients with an elevated d-dimer level, there was no 
significant difference between extended-duration betrixaban and a standard 
regimen of enoxaparin in the prespecified primary efficacy outcome. However, 
prespecified exploratory analyses provided evidence suggesting a benefit for 
betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX 
ClinicalTrials.gov number, NCT01583218.)
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Patients who are hospitalized for acute medical illnesses such as pneumonia, stroke, and heart failure are at increased 
risk for venous thromboembolism.1 Prolonged 
immobilization and risk factors such as an ele-
vated d-dimer level, an age of 75 years or older, 
cancer, or a history of venous thromboembolism 
increase this risk.2-5
Randomized, controlled trials of parenteral 
anticoagulants versus placebo in such hospitalized 
medical patients have shown a reduction of more 
than 50% in the rate of venous thromboembo-
lism, including fatal pulmonary embolism, with-
out an increase in major bleeding.6-10 Guidelines 
recommend the use of low-dose parenteral anti-
coagulants among patients at high risk for 
thromboembolism for 6 to 14 days but advise 
against extended-duration thromboprophylaxis 
after hospital discharge.11 However, the risk of 
pulmonary embolism and deep-vein thrombosis 
remains markedly increased for at least the first 
month after hospital discharge.12 In three previous 
trials — the Extended Clinical Prophylaxis in 
Acutely Ill Medical Patients (EXCLAIM) trial with 
enoxaparin, the Apixaban Dosing to Optimize 
Protection from Thrombosis (ADOPT) trial, and 
the Multicenter, Randomized, Parallel Group Effi-
cacy and Safety Study for the Prevention of Venous 
Thromboembolism in Hospitalized Acutely Ill Med-
ical Patients Comparing Rivaroxaban with Enoxa-
parin (MAGELLAN) trial — investigators did not 
identify an effective and safe treatment option 
during this vulnerable period.5,13,14 Therefore, we 
undertook a randomized trial of betrixaban, an 
oral, direct factor Xa inhibitor, for extended throm-
boprophylaxis in acutely ill medical patients.
Me thods
Study Design and Oversight
The Acute Medically Ill VTE (Venous Thrombo-
embolism) Prevention with Extended Duration 
Betrixaban (APEX) trial was a randomized, 
double-blind, double-dummy, active-controlled, 
multinational clinical trial.15 The study was de-
signed and supervised by an executive steering 
committee and sponsored by Portola Pharma-
ceuticals. Data were collected by Pharmaceutical 
Product Development, a contract research orga-
nization that was paid by the sponsor, and by 
the Duke Clinical Research Institute and Percu-
taneous–Pharmacologic Endoluminal Revascu-
larization for Unstable Syndromes Evaluation 
(PERFUSE), two academic research organizations. 
All three organizations had access to the full 
database to verify and analyze the results. All 
the authors had full access to the data and 
analyses and contributed to the first and subse-
quent drafts of the manuscript. The authors 
vouch for the accuracy and completeness of the 
data and all analyses, as well as for the fidelity 
of this report to the trial protocol, available with 
the full text of this article at NEJM.org.
The trial was conducted in accordance with 
the provisions of the Declaration of Helsinki and 
local regulations. The protocol was approved by 
the relevant local institutional review boards and 
ethics committees. Written informed consent was 
obtained from each patient before any study-
specific procedures were performed.
Patients, Treatments, and Follow-up
Patients were eligible if they were 40 years of age 
or older, had been hospitalized for less than 96 
hours for a specified acute medical illness (heart 
failure, respiratory failure, infectious disease, 
rheumatic disease, or ischemic stroke), and had 
reduced mobility and specific risk factors for 
venous thromboembolism. Detailed inclusion 
and exclusion criteria are provided in the Supple-
mentary Appendix, available at NEJM.org.
During the course of the trial, and after con-
sultation with and agreement by regulatory au-
thorities, we modified the protocol to enrich the 
trial population for patients at high risk for ve-
nous thromboembolism. (Details are provided in 
the Methods section in the Supplementary Ap-
pendix.) These protocol changes, which were 
adopted on June 4, 2014, required the presence 
of an elevated d-dimer level or an age of at least 
75 years as an entry criterion. We also modified 
the statistical analysis plan by establishing two 
cohorts within the overall study population. Co-
hort 1 included patients who had an elevated 
baseline d-dimer level (i.e., at least two times 
the upper limit of the normal range), and cohort 
2 included the patients in cohort 1 plus those 
who were 75 years of age or older.16 Local labora-
tory values of d-dimer were prespecified to de-
fine cohorts 1 and 2 for outcome analyses. The 
results of central laboratory testing of d-dimer 
performed with the use of STA-Liatest D-Di 
 (Stago) were used to define cohorts 1 and 2 in 
separate prespecified exploratory analyses.
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We used permuted blocks to stratify eligible 
patients according to geographic region (North 
America, Europe, Latin America, and Asia), entry 
criteria (enrolled in cohort 1 or not enrolled in 
cohort 1), and criteria for the dose of anticoagu-
lants (renal insufficiency [creatinine clearance, 
≥15 ml and <30 ml per minute], receipt of a 
concomitant strong P-glycoprotein inhibitor 
[i.e., amiodarone, verapamil, or quinidine, which 
can double the betrixaban exposure] without 
severe renal insufficiency, or neither) for a total 
of 24 strata.
An interactive voice-response system was used 
to randomly assign patients to receive one of 
two regimens: subcutaneous enoxaparin (at a 
dose of 40 mg once daily) for 10±4 days plus oral 
betrixaban placebo once daily for 35 to 42 days; 
or subcutaneous enoxaparin placebo once daily 
for 10±4 days plus oral betrixaban (at a loading 
dose of 160 mg for the first dose and then 80 mg 
once daily for 35 to 42 days). Patients with severe 
renal insufficiency received 50% of the prespeci-
fied dose of each study medication (i.e., 20 mg 
of enoxaparin or a loading dose of 80 mg of 
betrixaban and then 40 mg once daily). Patients 
who were receiving a concomitant P-glycopro-
tein inhibitor received a reduced dose of betrixa-
ban (40 mg once daily).
During follow-up, clinicians were instructed to 
confirm clinically suspected cases of deep-vein 
thrombosis by means of ultrasonography or 
other vascular-imaging technique and to con-
firm clinically suspected pulmonary embolism 
on computed tomography, a ventilation–perfusion 
lung scan, pulmonary angiography, or autopsy. 
In patients without clinically confirmed venous 
thromboembolism, mandatory ultrasonography 
was performed for the detection of asymptom-
atic deep-vein thrombosis after the administra-
tion of the last dose of a study medication or 
matching placebo between day 35 and day 42.15 
All the patients were followed for 30±5 days after 
the assessment on day 42.
Outcome Measures
All outcomes were assessed by an independent, 
central end-point adjudication committee whose 
members were unaware of treatment assign-
ments. There were two such committees — one 
for symptomatic outcomes (located at Duke 
Clinical Research Institute) and one for asymp-
tomatic ultrasonographic outcomes (located at 
EZUS Lyon of Université Claude Bernard Lyon, 
France).
The primary efficacy outcome was a compos-
ite of asymptomatic proximal deep-vein throm-
bosis between day 32 and day 47, symptomatic 
proximal or distal deep-vein thrombosis, symp-
tomatic nonfatal pulmonary embolism, or death 
from venous thromboembolism between day 1 and 
day 42. The two major secondary efficacy out-
comes were a composite of symptomatic venous 
thromboembolism through day 42 (death from 
venous thromboembolism, nonfatal pulmonary 
embolism, or symptomatic deep-vein thrombo-
sis) and a composite of asymptomatic proximal 
deep-vein thrombosis between day 32 and day 47, 
symptomatic deep-vein thrombosis (proximal or 
distal), nonfatal pulmonary embolism, or death 
from any cause through day 42.
The principal safety outcome was the occur-
rence of major bleeding at any point until 7 days 
after the discontinuation of all study medica-
tions. Bleeding events were classified according 
to the criteria of the International Society on 
Thrombosis and Haemostasis (ISTH) as major 
bleeding, clinically relevant nonmajor bleeding, 
and minimal bleeding.17,18 Definitions of all out-
come events are provided in the Supplementary 
Appendix. All outcome events in the trial proto-
col are provided in Table S1 in the Supplemen-
tary Appendix and categorized according to 
whether the events are included in this report.
Statistical Analysis
Plans for the statistical analysis have been report-
ed previously15,16 and are available at NEJM.org. 
The three cohorts that were included in the ef-
ficacy analysis were prespecified in a procedure 
with a fixed hierarchical sequence to adjust for 
the type I error rate.19 If betrixaban was superior 
to enoxaparin with respect to the primary efficacy 
outcome in cohort 1 (at an alpha level of 0.05), 
the trial was considered to have met its primary 
end point, and superiority with respect to the 
primary efficacy outcome was tested in cohort 2. 
If betrixaban was superior to enoxaparin in co-
hort 2, superiority with respect to the primary 
efficacy outcome was then evaluated in the over-
all study population. Subsequent analyses of the 
secondary end points were likewise conditioned 
on superiority with respect to the primary effi-
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cacy outcome. If such alpha thresholds were not 
met, subsequent prespecified analyses were con-
sidered to be exploratory.
Patients were eligible to be included in the 
efficacy analyses if they had received at least one 
dose of a study medication and had an adequate 
assessment of venous thromboembolism. In ad-
dition, we used the method of Quan et al.20 in 
sensitivity analyses to impute data for patients 
who did not have an adequate assessment of 
venous thromboembolism. Patients were eligible 
for the safety analyses if they had received at 
least one dose of an active study medication. For 
all efficacy outcomes, we used a Cochran–Mantel–
Haenszel model to estimate the risk ratio of the 
incidence rates (betrixaban vs. enoxaparin), strat-
ified according to two randomization factors: an 
elevated d-dimer level at baseline (as assessed in 
a local laboratory) and the criteria for the dose 
of anticoagulants (severe renal dysfunction, re-
ceipt of a concomitant P-glycoprotein inhibitor, 
or neither). Bleeding events were analyzed with-
out stratification. All statistical tests were two-
sided with a type I error rate of 5.0%; two-sided 
95% confidence intervals were calculated. Sub-
group analyses were presented as forest plots for 
subgroup risk ratios and confidence intervals; 
statistical tests of interaction were used. A de-
scription of the sample-size calculation is pro-
vided in the Methods section in the Supplemen-
tary Appendix.
R esult s
Study Populations
From March 2012 through November 2015, we 
screened 8589 patients at 460 sites in 35 coun-
tries. Of these patients, 7513 were found to be 
eligible to participate in the study and under-
went randomization (3759 in the betrixaban 
group and 3754 in the enoxaparin group) (Fig. 1). 
The characteristics of the patients at baseline, 
the frequency of acute medical conditions, and 
risk factors for venous thromboembolism were 
similar in the two groups (Table 1).
The definitions of the analysis populations 
are provided in Table S2 in the Supplementary 
Appendix. A total of 72 patients (1.0% of those 
who underwent randomization) were excluded 
from all analyses because they did not receive a 
study drug, and 1155 patients (15.4% of those 
who underwent randomization) were excluded 
from the efficacy analyses because they did not 
have a symptomatic event associated with venous 
thromboembolism and did not undergo ultraso-
nography between day 32 and day 47. Compari-
sons of the baseline characteristics of the pa-
tients who were included in each of the efficacy 
analysis populations are provided in Tables S3, 
S4, and S5 in the Supplementary Appendix. The 
median duration of active treatment was 36 days 
(interquartile range, 34 to 39) in the betrixaban 
group and 9 days (interquartile range, 7 to 13) 
in the enoxaparin group.
Efficacy Outcomes
The primary outcome and its components in 
each of the trial cohorts are shown in Table 2. 
In cohort 1, the primary efficacy outcome oc-
curred in 6.9% of the betrixaban group and 
8.5% of the enoxaparin group (relative risk in 
the betrixaban group, 0.81; 95% confidence in-
terval [CI], 0.65 to 1.00; P = 0.054). This first test 
in the sequence of cohorts did not meet the pre-
specified threshold for statistical significance; 
therefore, all subsequent prespecified efficacy 
outcomes were considered to be exploratory and 
were not used to draw conclusions regarding 
statistical significance.
In cohort 2, the primary efficacy outcome oc-
curred in 5.6% of the betrixaban group and 7.1% 
of the enoxaparin group (relative risk, 0.80; 95% 
CI, 0.66 to 0.98; P = 0.03). In the overall popula-
tion, the primary efficacy outcome occurred in 
5.3% and 7.0% of the patients, respectively (rela-
tive risk, 0.76; 95% CI, 0.63 to 0.92; P = 0.006). In 
sensitivity analyses in which we used imputation 
to account for missing data, similar results were 
obtained in cohorts 1 and 2 (Table S6 in the 
Supplementary Appendix). When we defined 
cohorts 1 and 2 using central laboratory d-dimer 
values, the use of betrixaban was associated 
with a lower rate of the primary outcome in all 
analyses (Table S7 in the Supplementary Appen-
dix). There was no evidence of heterogeneity 
with respect to the primary outcome according 
to cohort or in the prespecified subgroups (Figs. 
S1, S2, and S3 in the Supplementary Appendix).
The key secondary end points for each cohort 
are provided in Table 2. In the overall popula-
tion, the first secondary efficacy outcome, symp-
tomatic venous thromboembolism, occurred in 
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0.9% of betrixaban group and 1.5% of the 
enoxaparin group (relative risk, 0.64; 95% CI, 
0.42 to 0.98; P = 0.04). Time-to-event curves for 
symptomatic venous thromboembolism are pro-
vided in Figure S4 in the Supplementary Appen-
dix. The second secondary efficacy outcome, 
defined as the primary efficacy outcome with 
the replacement of death from venous thrombo-
embolism by death from any cause, occurred in 
9.2% of the betrixaban group and 10.8% of the 
enoxaparin group in the overall population (rela-
tive risk, 0.85; 95% CI, 0.73 to 0.98; P = 0.02).
The net clinical benefit (a composite of any 
component of the primary efficacy end point or 
principal safety outcome) occurred in 5.8% of 
the betrixaban group and 7.3% of the enoxaparin 
group (relative risk, 0.78; 95% CI, 0.65 to 0.95; 
P = 0.01).
Safety Outcomes
In the overall safety population, major bleeding 
occurred in 0.7% of the betrixaban group and 
0.6% of the enoxaparin group (relative risk, 1.19; 
95% CI, 0.67 to 2.12; P = 0.55) (Table 3). There 
were two cases of intracranial bleeding in the 
betrixaban group and seven in the enoxaparin 
group. There was one case of fatal bleeding in 
each group. The secondary safety outcome, major 
or clinically relevant nonmajor bleeding, occurred 
in 3.1% of the betrixaban group and 1.6% of the 
enoxaparin group (relative risk, 1.97; 95% CI, 
1.44 to 2.68; P<0.001). (The prespecified sub-
groups with respect to the principal safety out-
come are described in Fig. S5 in the Supplemen-
tary Appendix.)
New ischemic stroke as adjudicated by the 
central committee occurred in 18 of 3716 patients 
(0.5%) in the betrixaban group and 34 of 3716 
patients (0.9%) in the enoxaparin group (relative 
risk, 0.53; 95% CI, 0.30 to 0.94; P = 0.03). The 
corresponding numbers for all types of strokes 
were 24 of 3716 patients (0.6%) and 41 of 3716 
(1.1%), respectively (relative risk, 0.59; 95% CI, 
0.35 to 0.97; P = 0.03).
Discussion
In the APEX trial, we compared the use of 
 extended-duration betrixaban (for 35 to 42 days) 
with a standard enoxaparin regimen (10±4 days) 
for thromboprophylaxis in patients who were 
hospitalized with an acute medical illness. The 
study design specified that the primary outcome 
would be analyzed in a hierarchical fashion, first 
in patients who had an elevated d-dimer level 
(cohort 1), second in patients with either an ele-
vated d-dimer level or an age of at least 75 years 
(cohort 2), and third in the entire trial popula-
tion. Because there was no significant between-
group difference in the primary outcome in co-
hort 1 (P = 0.054), the protocol specified that all 
subsequent analyses were considered to be explor-
atory. However, taken together, these additional 
analyses provide support for the interpretation 
that the risk of venous thromboembolism was 
lower with betrixaban than with enoxaparin.
The decision to perform hierarchical testing of 
trial outcomes in subgroups of the overall trial 
population was based on the expectation that 
patients with an elevated d-dimer level or an age 
of at least 75 years would represent a subgroup 
enriched for both a greater risk of venous 
thromboembolism and a greater benefit of ex-
tended-duration antithrombotic therapy. These 
expectations were based on data for similar pa-
tients who were enrolled in the MAGELLAN 
trial of rivaroxaban. We found that patients with 
an elevated d-dimer level or who were 75 years 
of age or older were at modestly higher risk; 
however, we did not find a greater benefit of 
extended-duration betrixaban in this group using 
d-dimer levels that were assessed in a local 
laboratory. Thus, in the primary analysis, the 
Figure 1 (facing page). Enrollment, Reasons for Exclusion, 
and Outcomes.
The modified intention-to-treat population included all 
the patients who received at least one dose of a study 
medication. The first secondary efficacy outcome (symp-
tomatic venous thromboembolism) was analyzed in this 
population of patients (3721 in the betrixaban group 
and 3720 in the enoxaparin group). Among the patients 
in the modified intention-to-treat population, 609 in the 
betrixaban group and 546 in the enoxaparin group had 
no available ultrasonographic data and did not have a 
fatal or symptomatic thromboembolic event; these pa-
tients were excluded from the main efficacy analysis. 
Cohort 1 included patients who had an elevated baseline 
d-dimer level (i.e., at least two times the upper limit of 
the normal range), and cohort 2 included the patients in 
cohort 1 plus those who were 75 years of age or older. 
The primary efficacy outcome population included all the 
patients in the trial. Additional information about the analy-
sis groups is provided in Table S2 in the Supplementary 
Appendix. VTE denotes venous thromboembolism.
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Characteristic
Betrixaban 
(N = 3759)
Enoxaparin 
(N = 3754)
Age — yr 76.6±8.46 76.2±8.31
Male sex — no. (%) 1705 (45.4) 1720 (45.8)
Mean weight — kg 79.84 80.74
Body-mass index† 29.21±6.60 29.54±6.67
Median no. of days of hospitalization (IQR) 10 (7–4) 10 (8–14)
Creatinine clearance — no. (%)‡
<15 ml/min    1 (<0.1) 0
15 to <30 ml/min 174 (4.6) 150 (4.0)
30 to <60 ml/min 1602 (42.6) 1531 (40.8)
60 to <90 ml/min 1299 (34.6) 1346 (35.9)
≥90 ml/min  672 (17.9)  716 (19.1)
Missing data  11 (0.3)  11 (0.3)
Race or ethnic group — no. (%)§
White 3503 (93.2) 3518 (93.7)
Asian   9 (0.2)   7 (0.2)
Black  74 (2.0)  73 (1.9)
Other 173 (4.6) 156 (4.2)
Concomitant P-glycoprotein inhibitor — no. (%)  677 (18.0)  649 (17.3)
Previous thromboprophylaxis ≤96 hr — no. (%) 1928 (51.3) 1879 (50.1)
Acute medical condition — no. (%)
Heart failure 1677 (44.6) 1672 (44.5)
Infection 1112 (29.6) 1058 (28.2)
Respiratory failure  448 (11.9)  474 (12.6)
Ischemic stroke  411 (10.9)  432 (11.5)
Rheumatic disorder 109 (2.9) 117 (3.1)
Risk factor for venous thromboembolism — no. (%)
Level of d-dimer ≥2 × ULN 2341 (62.3) 2332 (62.1)
Age ≥75 yr 2575 (68.5) 2517 (67.0)
History of cancer  466 (12.4)  443 (11.8)
History of deep-vein thrombosis or pulmonary embo-
lism
312 (8.3) 296 (7.9)
History of New York Heart Association class III or IV 
heart failure
853 (22.7) 865 (23.0)
Concurrent acute infectious disease 602 (16.0) 620 (16.5)
Severe varicosities 702 (18.7) 690 (18.4)
Hormone-replacement therapy 43 (1.1) 31 (0.8)
Hereditary or acquired thrombophilia   3 (<0.1)  5 (0.1)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups. IQR denotes inter-
quartile range, and ULN upper limit of the normal range.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Creatinine clearance levels were calculated with the use of the Cockcroft–Gault equation on the basis of creatinine levels 
on day 1. To convert the values for creatinine to micromoles per liter, multiply by 88.4.
§  Race or ethnic group was self-reported. “Other” includes patients who were categorized as Native American, Alaska 
Native, Native Hawaiian or Pacific Islander, other race, or mixed race.
Table 1. Characteristics of the Patients at Baseline.*
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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Outcome Betrixaban Enoxaparin
Relative Risk 
(95% CI) P Value
no./total no. (%)
Principal safety outcome in cohort 1
Major bleeding  15/2311 (0.6)  17/2310 (0.7) 0.88 (0.44–1.76) 0.72
Decrease in hemoglobin of ≥2 g/dl  9 6 NA
Transfusion of ≥2 units of blood 10 9 NA
Critical-site bleeding  1 7 NA
Fatal bleeding  0 1 NA
Major or clinically relevant nonmajor bleeding  72/2311 (3.1)  44/2310 (1.9) 1.64 (1.13–2.37) 0.009
Principal safety outcome in cohort 2
Major bleeding  25/3402 (0.7)  21/3387 (0.6) 1.19 (0.66–2.11) 0.56
Decrease in hemoglobin of ≥2 g/dl 12 8 NA
Transfusion of ≥2 units of blood 18 9 NA
Critical-site bleeding  3 9 NA
Fatal bleeding  1 1 NA
Major or clinically relevant nonmajor bleeding 110/3402 (3.2)  58/3387 (1.7) 1.89 (1.38–2.59) <0.001
Principal safety outcome in overall safety population
Major bleeding  25/3716 (0.7)  21/3716 (0.6) 1.19 (0.67–2.12) 0.55
Decrease in hemoglobin of ≥2 g/dl 12 8 NA
Transfusion of ≥2 units of blood 18 9 NA
Critical-site bleeding  3 9 NA
Fatal bleeding  1 1 NA
Major or clinically relevant nonmajor bleeding 116/3716 (3.1)  59/3716 (1.6) 1.97 (1.44–2.68) <0.001
Other safety outcomes in all patients†
Any adverse event 2005/3716 (54.0) 1931/3716 (52.0)
Any serious adverse event 657/3716 (17.7) 615/3716 (16.6)
Death
Any cause 210/3716 (5.7) 215/3716 (5.8)
Bleeding 1/3716 (<0.1) 1/3716 (<0.1)
Venous thromboembolism 15/3716 (0.4) 26/3716 (0.7)
Other cardiovascular cause
Heart failure or cardiogenic shock 40/3716 (1.1) 56/3716 (1.5)
Arrhythmic disorder 0 1/3716 (<0.1)
Myocardial infarction 11/3716 (0.3) 8/3716 (0.2)
Ischemic stroke 24/3716 (0.6) 28/3716 (0.8)
Noncardiovascular cause 95/3716 (2.6) 76/3716 (2.0)
Undetermined or unknown cause 24/3716 (0.6) 19/3716 (0.5)
Stroke
Any 24/3716 (0.6) 41/3716 (1.1)
Ischemic 18/3716 (0.5) 34/3716 (0.9)
*  Data for the principal safety outcomes include events that occurred up to 7 days after the last dose of a study drug. 
Other safety outcomes were evaluated during the entire duration of the trial.
†  Relative risks and P values are not included for this category because the protocol did not specify a comparative analy-
sis of adverse events.
Table 3. Safety Outcomes.*
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fact that there were fewer patients in cohort 1 
than in either cohort 2 or the overall population 
resulted in a diminished statistical power with-
out a corresponding gain in efficacy. A benefit 
for betrixaban was seen when the study cohorts 
were evaluated in exploratory analyses according 
to the more specific d-dimer testing used in the 
central laboratory.
The widespread use of preventive strategies 
hinges on the safety of the intervention. Betrixa-
ban was associated with a low frequency of major 
bleeding and fatal bleeding. Unlike enoxaparin 
in the EXCLAIM trial, apixaban in the ADOPT 
trial, and rivaroxaban in the MAGELLAN trial, 
the use of extended-duration betrixaban in our 
trial was not associated with significantly more 
major bleeding than standard-duration enoxapa-
rin,5,13,14 although there was significantly more 
clinically relevant nonmajor bleeding. Intracra-
nial bleeding was infrequent in the two groups, 
but the rate was lower in the betrixaban group 
than in the enoxaparin group.
In the United States, approximately 7 million 
acutely ill medical patients at increased risk for 
venous thromboembolism are admitted to the 
hospital every year.21 Such patients account for 
more than 20% of the attributable risk for ve-
nous thromboembolism.22 In the European Union 
and the United States combined, more than 2 mil-
lion clinical events associated with venous throm-
boembolism occur annually in the general popu-
lation.23,24 In our trial, betrixaban was associated 
with a reduction in the rates of symptomatic 
events and asymptomatic deep-vein thrombosis, 
both of which are associated with fatal and non-
fatal pulmonary embolism and death in acutely 
ill medical patients.25 Decreasing the rate of ve-
nous thromboembolism in this patient popula-
tion would benefit public health.
In such patients, parenteral anticoagulants 
may be used to reduce the risk of venous throm-
boembolism during hospitalization, but such 
drugs are rarely continued after discharge. The 
trend toward shorter hospitalizations may have 
the unintended consequence that patients receive 
a short duration of thromboprophylaxis that is 
inadequate. In exploratory analyses in our trial, 
we found that oral betrixaban can be extended 
after discharge to reduce the rate of venous 
thromboembolism among patients who are cat-
egorized according to their admission diagnoses 
and predefined risk factors.
The most important limitation of our trial 
was the fact that approximately 15% of enrolled 
patients underwent either no or inadequate ul-
trasonography and therefore could not be in-
cluded in the main analyses of the efficacy out-
comes. However, this limitation was also seen in 
similarly designed trials, such as ADOPT and 
MAGELLAN, and indeed the frequency of miss-
ing data was lower in our trial.5,13,14 The fact that 
the rate of symptomatic events was lower in the 
betrixaban group than in the enoxaparin group 
supports the findings of the primary outcome 
analyses and suggests that the missing data did 
not substantially influence the results.
In conclusion, in a comparison of extended-
duration thromboprophylaxis with betrixaban 
and standard-duration enoxaparin in acutely ill 
medical patients, there was no significant 
 between-group difference in the prespecified pri-
mary efficacy outcome among the patients with 
an elevated d-dimer level. However, prespecified 
exploratory analyses provided evidence suggest-
ing a benefit for betrixaban.
Supported by Portola Pharmaceuticals.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
References
1. Cohen AT, Alikhan R, Arcelus JI, et al. 
Assessment of venous thromboembolism 
risk and the benefits of thromboprophy-
laxis in medical patients. Thromb Hae-
most 2005; 94: 750-9.
2. Samama MM. An epidemiologic study 
of risk factors for deep vein thrombosis 
in medical outpatients: the Sirius study. 
Arch Intern Med 2000; 160: 3415-20.
3. Alikhan R, Cohen AT, Combe S, et al. 
Risk factors for venous thromboembo-
lism in hospitalized patients with acute 
medical illness: analysis of the MEDENOX 
Study. Arch Intern Med 2004; 164: 963-8.
4. Cohen AT, Spiro TE, Spyropoulos AC, 
et al. D-dimer as a predictor of venous 
thromboembolism in acutely ill, hospital-
ized patients: a subanalysis of the random-
ized controlled MAGELLAN trial. J Thromb 
Haemost 2014; 12: 479-87.
5. Hull RD, Schellong SM, Tapson VF, 
et al. Extended-duration venous thrombo-
embolism prophylaxis in acutely ill medi-
cal patients with recently reduced mobil-
ity: a randomized trial. Ann Intern Med 
2010; 153: 8-18.
6. Dentali F, Douketis JD, Gianni M, Lim 
W, Crowther MA. Meta-analysis: antico-
agulant prophylaxis to prevent symptom-
atic venous thromboembolism in hospi-
talized medical patients. Ann Intern Med 
2007; 146: 278-88.
7. Samama MM, Cohen AT, Darmon J-Y, 
et al. A comparison of enoxaparin with 
placebo for the prevention of venous 
thromboembolism in acutely ill medical 
patients. N Engl J Med 1999; 341: 793-800.
8. Fraisse F, Holzapfel L, Couland JM, 
et al. Nadroparin in the prevention of deep 
vein thrombosis in acute decompensated 
COPD. Am J Respir Crit Care Med 2000; 
161: 1109-14.
9. Leizorovicz A, Cohen AT, Turpie AG, 
Olsson CG, Vaitkus PT, Goldhaber SZ. 
Randomized, placebo-controlled trial of 
The New England Journal of Medicine 
Downloaded from nejm.org on January 3, 2019. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;6 nejm.org August 11, 2016544
Betrixaban in Acutely Ill Medical Patients
dalteparin for the prevention of venous 
thromboembolism in acutely ill medical 
patients. Circulation 2004; 110: 874-9.
10. Cohen AT, Davidson BL, Gallus AS, 
et al. Efficacy and safety of fondaparinux 
for the prevention of venous thromboem-
bolism in older acute medical patients: 
randomised placebo controlled trial. BMJ 
2006; 332: 325-9.
11. Kahn SR, Lim W, Dunn AS, et al. Pre-
vention of VTE in nonsurgical patients: 
Antithrombotic Therapy and Prevention 
of Thrombosis, 9th ed: American College 
of Chest Physicians Evidence-Based Clini-
cal Practice Guidelines. Chest 2012; 141: 2 
Suppl: e195S-226S.
12. Amin AN, Varker H, Princic N, Lin J, 
Thompson S, Johnston S. Duration of 
venous thromboembolism risk across a 
continuum in medically ill hospitalized 
patients. J Hosp Med 2012; 7: 231-8.
13. Cohen AT, Spiro TE, Büller HR, et al. 
Rivaroxaban for thromboprophylaxis in 
acutely ill medical patients. N Engl J Med 
2013; 368: 513-23.
14. Goldhaber SZ, Leizorovicz A, Kakkar 
AK, et al. Apixaban versus enoxaparin for 
thromboprophylaxis in medically ill pa-
tients. N Engl J Med 2011; 365: 2167-77.
15. Cohen AT, Harrington R, Goldhaber 
SZ, et al. The design and rationale for the 
Acute Medically Ill Venous Thromboem-
bolism Prevention with Extended Dura-
tion Betrixaban (APEX) study. Am Heart J 
2014; 167: 335-41.
16. Cohen AT, Harrington R, Goldhaber 
SZ, et al. Recognition of biomarker identi-
fied high-risk patients in the acute medi-
cally ill venous thromboembolism preven-
tion with extended duration betrixaban 
study resulting in a protocol amendment. 
Am Heart J 2015; 169: 186-7.
17. Schulman S, Kearon C, Subcommittee 
on Control of Anticoagulation of the Scien-
tific and Standardization Committee of the 
International Society on Thrombosis and 
Haemostasis. Definition of major bleeding 
in clinical investigations of antihemostatic 
medicinal products in non-surgical pa-
tients. J Thromb Haemost 2005; 3: 692-4.
18. The van Gogh Investigators. Idrapari-
nux versus standard therapy for venous 
thromboembolic disease. N Engl J Med 
2007; 357: 1094-104.
19. Westfall PH, Krishen A, Young SS. 
Using prior information to allocate sig-
nificance levels for multiple endpoints. 
Stat Med 1998; 17: 2107-19.
20. Quan H, Zhang D, Zhang J, Devla-
mynck L. Analysis of a binary composite 
endpoint with missing data in compo-
nents. Stat Med 2007; 26: 4703-18.
21. Anderson FA Jr, Zayaruzny M, Heit JA, 
Fidan D, Cohen AT. Estimated annual 
numbers of US acute-care hospital pa-
tients at risk for venous thromboembo-
lism. Am J Hematol 2007; 82: 777-82.
22. Heit JA, O’Fallon WM, Petterson TM, 
et al. Relative impact of risk factors for 
deep vein thrombosis and pulmonary em-
bolism: a population-based study. Arch 
Intern Med 2002; 162: 1245-8.
23. Cohen AT, Agnelli G, Anderson FA, 
et al. Venous thromboembolism (VTE) in 
Europe: the number of VTE events and as-
sociated morbidity and mortality. Thromb 
Haemost 2007; 98: 756-64.
24. Raskob GE, Angchaisuksiri P, Blanco 
AN, et al. Thrombosis: a major contribu-
tor to global disease burden. Arterioscler 
Thromb Vasc Biol 2014; 34: 2363-71.
25. Vaitkus PT, Leizorovicz A, Cohen AT, 
Turpie AG, Olsson CG, Goldhaber SZ. 
Mortality rates and risk factors for asymp-
tomatic deep vein thrombosis in medical 
patients. Thromb Haemost 2005; 93: 76-9.
Copyright © 2016 Massachusetts Medical Society.
an nejm app for iphone
The NEJM Image Challenge app brings a popular online feature to the smartphone. 
Optimized for viewing on the iPhone and iPod Touch, the Image Challenge app lets 
you test your diagnostic skills anytime, anywhere. The Image Challenge app 
randomly selects from 300 challenging clinical photos published in NEJM,  
with a new image added each week. View an image, choose your answer,  
get immediate feedback, and see how others answered.  
The Image Challenge app is available at the iTunes App Store.
The New England Journal of Medicine 
Downloaded from nejm.org on January 3, 2019. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
